Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2A | P28223 | 8/20 | 0.68 |
| ▸ | HTR2C | P28335 | 6/20 | 0.63 |
| ▸ | DRD2 | P14416 | 5/20 | 0.62 |
| ▸ | BCHE | P06276 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.46 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MPO | P05164 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.41 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26675957 | 0.82 | MAOA (0.51) | HTR2AHTR2CDRD2BCHECHRNA7 | |
| SCHEMBL26508424 | 0.82 | HTR2A (0.68) | HTR2AHTR2CDRD2BCHECHRNA7 | |
| SCHEMBL26508371 | 0.82 | HTR2A (0.72) | HTR2AHTR2CDRD2BCHEHRH3 | |
| SCHEMBL25772732 | 0.82 | HTR2A (0.68) | HTR2AHTR2CDRD2BCHEHRH3 | |
| SCHEMBL26508362 | 0.82 | HTR2A (0.68) | HTR2AHTR2CDRD2BCHEHRH3 | |
| SCHEMBL26508413 | 0.79 | HTR2A (0.64) | HTR2AHTR2CDRD2BCHEHRH3 | |
| SCHEMBL26508411 | 0.78 | HTR2A (0.63) | HTR2AHTR2CDRD2BCHEHRH3 | |
| SCHEMBL9026523 | 0.78 | HTR2A (0.66) | HTR2AHTR2CDRD2BCHEHRH3 | |
| SCHEMBL7648046 | 0.78 | HTR2A (1.00) | HTR2AHTR2CDRD2KCNH2 | |
| SCHEMBL8524422 | 0.77 | HTR2A (1.00) | HTR2AHTR2CDRD2CHRNA7KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322735-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230322735-A1 | AZETIDINYL TRYPTAMINES AND METHODS OF TREATING PSYCHIATRIC DISORDERS | TPH2, TPH1, HTR2A | HTR2A 3/4885HTR2C 4/4885DRD2 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.